stöver lehmann consulting
DESCRIPTION
Stöver Lehmann Consulting. By Manon St över Matthieu Lehmann Lausanne, June 23 rd 2006. Agenda. Who are we ? Why are we here today ? What has been done until today? What can be achieved and how?. SLC – Team presentation. Manon Stöver Co-founder - PowerPoint PPT PresentationTRANSCRIPT
Stöver Lehmann
ConsultingBy
Manon Stöver
Matthieu Lehmann
Lausanne, June 23rd 2006
Stöver Lehmann Consulting
2
AgendaAgenda
Who are we ?Why are we here today ?What has been done until
today?What can be achieved and
how?
Stöver Lehmann Consulting
3
SLC – Team presentationSLC – Team
presentation Manon Stöver
Co-founder Expertise in investment within the Petroleum Industry
Matthieu Lehmann Co-founder Expertise in Biotechnologies and Process Development
Stöver Lehmann Consulting
4
SLC - PhilosophySLC - Philosophy
Our orientation is to raise funds for refreshing and interesting research and development
Our vision is to support ideas with huge potential for humanity
We are looking for revolution more than evolution
Stöver Lehmann Consulting
5
SLC – Past Successes
SLC – Past Successes
SLC’s past successes in raising funds are in the field of research and development: BioXell (Cancer therapy) 7TM Pharma (Virology) H2FUEL (hydrogen engine) HydroNEXT (biofuel cell)
Stöver Lehmann Consulting
6
Dr. de Grey’s presentation
Dr. de Grey’s presentation
Engineering background from computer sciences
Previous work in bioinformatics
Current research in biogerontology
His vision:
Reengineering the approach of how to cure aging
Stöver Lehmann Consulting
7
What is Unlimited Life?
What is Unlimited Life?
A research institute in biogerontology
A concept: Curing aging
The final mission of UL is to provide people with medecines to cure aging
Metabolism Damage Pathology
Gerontology Engineering Geriatrics
Stöver Lehmann Consulting
8
More about Unlimited Life
More about Unlimited Life
Home institution for research is Cambridge
Research is highly potential for several breakthroughs : ‘We are already on the road, it’s definitely more than a simple concept !’
Absolutely refreshing approach of anti-aging process: start at the roots of the process
At the beginning of something revolutionary
Stöver Lehmann Consulting
9
The 7 deadly things principle
The 7 deadly things principle
Basics of Dr. de Grey research
Damages rising with age1. Cell loss, cell atrophy2. Nuclear [epi]mutations (only
cancer matters)3. Mutant mitochondria4. Death-resistant cells5. Extracellular crosslinks6. Extracellular junk7. Intracellular junk
Stöver Lehmann Consulting
10
Today’s FocusToday’s Focus
Advise to improve funding of Unlimited Life research
Why are we concerned ? We believe in our customer competencies
We may change the world Aging is the most fatal and the first cause of death on Earth
Life is a gift, we must fight to keep it as hard as we fight for our freedom
Stöver Lehmann Consulting
11
Competitive Anti-Aging Researches
Competitive Anti-Aging Researches
Current technologies to slow the aging process Cryonic therapy Chemical drugs (DHEA) Medicines based on proteins
Plastic surgery Vitamins and food supplements
Stöver Lehmann Consulting
12
Results for current Anti-Aging
Results for current Anti-Aging
Results obtained from research Slowing down the process of aging
Mask the external signs of aging Small improvement on the origin of aging process
None of these technology treated aging from its roots
NB! These technologies are not competitive with the results of Dr. de Grey’s research
Stöver Lehmann Consulting
13
Origin of previous raised funds
Origin of previous raised funds
Past funds Winning the Mprize: donations for continuing research
Expenses contributions Donation of Air miles
Who are these investors ? Individuals Foundations
Stöver Lehmann Consulting
14
Money raised from these funds
Money raised from these funds
Funds raised Mprize: $ 3.5 million Donations: $ 218’005 Cost expenses: $ 89’756
Air miles: 360’374 milesGood starting point but obviously not
enough !
Stöver Lehmann Consulting
15
Dr. de Grey’s request for funding
Dr. de Grey’s request for funding
Dr. de Grey objectives: $100M/year of funding for the next 10 years
Creating research institutes all over the world
Investors are not to draw any direct benefit from providing funding
Stöver Lehmann Consulting
16
Possible solutionsPossible solutions
Organizational improvements
Promotion improvements Improvement of current funding ways
New funding ways
Stöver Lehmann Consulting
17
Organizational improvements
Organizational improvements
Organizational aspectDefine milestones/targets
Build a teamFind a ‘face’ for funding leader
Stöver Lehmann Consulting
18
Promotion improvements
Promotion improvements
Generate publicity Newspapers Broadcasting of documentaries
Universities Advertisements Exhibition
Nobel price for medicine
Stöver Lehmann Consulting
19
Improvement of current funding ways
Improvement of current funding ways
Donations
Other foundations
Individuals
Air miles
Stöver Lehmann Consulting
20
Foundations and Individuals
Foundations and Individuals
Aim at other foundations: AIDS association Cancer therapy association Arthritis Foundation Biological Trust
Convince individuals: Wealthy philanthropic people
Stöver Lehmann Consulting
21
AirmilesAirmiles
Change the law Airline companies might write off their airmiles older than 20y to foundations
Opportunity to raise billions of airmiles
Very convenient for both parties
Stöver Lehmann Consulting
22
New funding waysNew funding ways
Business Angels
Open source research
Partnerships
VCs
Stöver Lehmann Consulting
23
Business angelsBusiness angels
With certain characteristics: High personal interest in the research
Diversifying his/her investments Maybe (s)he will give a billion
Examples Donald Trump Hugh Hefner Bill Gates Larry Ellison
Stöver Lehmann Consulting
24
Larry EllisonLarry Ellison
Founder of Oracle
Almost as wealthy as Bill
Gates
Human benefactor
What is more prestigious
than investing in first
cause of death
Stöver Lehmann Consulting
25
Open sourceOpen source
No profits involvement Access to a huge community Low and shared cost Increase in time efficiency and productivity
High demanding process from a controlling aspect
Stöver Lehmann Consulting
26
Open source in our case
Open source in our case
Applicable on secondary level of research
Set up an association with confidential agreement
Create different virtual institutes around the world
Stöver Lehmann Consulting
27
PartnershipPartnership
Partners Cooperation in research; such as Cryogenics
Set up subsidiaries with pharmaceuticals
VCs with pharmaceuticals in the portfolio
Business angels with certain interests
To attract partners: certain level of leverage needed Define milestones/targets Create a source of revenues
Stöver Lehmann Consulting
28
Venture CapitalistVenture Capitalist
Involvement in the management and the ownership
Huge amount money can be brought on the table
Examples Cardinal Partners Polaris Venture Partners Techno Venture Management Novartis Bioventures Fund Cargill Ventures Three Arch Partners
Stöver Lehmann Consulting
29
Funding scheduleFunding schedule
First two years Research set up
Define milestones/targets for third parties
Alliances with anti-aging clinics to set up globally research institutes at universities
Create a team Use of benefits of an open source research
Funds Foundations and prices Business Angels Adjust budget
Stöver Lehmann Consulting
30
Funding scheduleFunding schedule
Next three years Involvement of VCs Creating revenues (seminars, meetings, publishing books, magazines)
Partnership with pharmaceutical companies regarding first mover advantage for commercial use
Stöver Lehmann Consulting
31
Financial Scheme - Sources
Financial Scheme - Sources
SourcesYear 1
Year 2
Year 3
Year 4
Year 5
Donations
0.2 0.2 0.4 0.5 0.5
VCs - - 2.1 6.9 6.8
BAs 4.3 4.3 2.0 2.0 2.0
Others 0.5 0.5 0.5 0.6 0.7
Total 5 5 5 10 10
Stöver Lehmann Consulting
32
Financial scheme - Uses
Financial scheme - Uses
Uses Year 1
Year 2
Year 3
Year 4
Year 5
Current expenditures
0.1 0.1 0.1 0.1 0.1
Promotion 0.1 0.1 0.5 0.5 0.5
Publishing
0.1 0.1 0.2 0.2 0.2
Research 4.5 4.5 9 9 9
Others 0.2 0.2 0.2 0.2 0.2
Stöver Lehmann Consulting
33
ConclusionConclusion
We have investigated
possibilities for
funding
within the requests
outside the requests
Who dares wins…